Iovance Biotherapeutics grants stock options to 21 new employees under Nasdaq rules.

Iovance Biotherapeutics approved inducement stock options for 111,615 shares to 21 new non-executive employees on October 15, 2026. These options have an exercise price of $14.72 and vest over three years, aligning employee incentives with company growth. The grants were made under Nasdaq Listing Rule 5635(c)(4) and the company's 2021 Inducement Plan. This move supports Iovance's ongoing innovation in cancer therapies and its expanding workforce.

As of Oct 17, 2026 04:11 WIB, Iovance Biotherapeutics (IOVA) trades at USD 13.63 on Pluang, slightly below its 52-week high of USD 14.82 but well above the 52-week low of USD 1.81. Despite the recent inducement stock option grants, the stock is down 7.40% in the last day with a market cap of $6.67 billion. Pluang order activity shows a full sell sentiment at 100%, reflecting cautious investor behavior at this price level.